Optibrium

The four main considerations that any leader should take into account to successfully implement AI in their organization are explored here.

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Semeta™ offers high sensitivity and superior precision for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery.

The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking. The software promotes collaboration within and across teams for more cohesive workflows

Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than other approaches.

Optibrium, announced that its drug discovery platform, StarDrop, is now also available in the cloud environment.

Backed by six years’ research, the new StarDrop Metabolism module combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates.

Optibrium, announced the acquisition of BioPharmics LLC, expanding its 3D drug design and modelling offering. Bringing decades of experience in computational chemistry and biology.

Optibrium and PostEra have announced a collaboration to integrate Optibrium’s StarDrop platform with PostEra’s Manifold software.

Optibrium has announced the appointment of Steve Yemm as Chief Commercial Officer.